Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
RLMD 
Relmada Therapeutics Inc (RLMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: RLMD (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 330.73M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 3 | Beta 0.83 | 52 Weeks Range 0.24 - 5.12 | Updated Date 11/29/2025 |
52 Weeks Range 0.24 - 5.12 | Updated Date 11/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -102.41% | Return on Equity (TTM) -196.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 258914549 | Price to Sales(TTM) - |
Enterprise Value 258914549 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.54 | Shares Outstanding 73333622 | Shares Floating 65449524 |
Shares Outstanding 73333622 | Shares Floating 65449524 | ||
Percent Insiders 10.75 | Percent Institutions 18.88 |
Upturn AI SWOT
Relmada Therapeutics Inc
Company Overview
History and Background
Relmada Therapeutics Inc. was founded in 2008 and is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system (CNS) diseases. A significant milestone was its focus on developing dextromethorphan-based therapies for neurological and psychiatric conditions, including depression and epilepsy.
Core Business Areas
- Neurological and Psychiatric Disorders: Relmada Therapeutics is primarily focused on developing innovative therapies for underserved neurological and psychiatric disorders. Their core efforts are concentrated on advancing their lead product candidates through clinical trials with the aim of addressing significant unmet medical needs in these areas.
Leadership and Structure
The leadership team typically includes a CEO, Chief Medical Officer, Chief Financial Officer, and a Board of Directors comprised of individuals with expertise in biotechnology, pharmaceuticals, and business management. The organizational structure is designed to support its clinical-stage development and regulatory affairs.
Top Products and Market Share
Key Offerings
- REL-1017 (Leukine): REL-1017 is Relmada's lead product candidate, a novel oral N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of Major Depressive Disorder (MDD) and potentially other CNS conditions. It is designed to be a rapid-acting antidepressant. No specific market share data is available as it is not yet approved. Key competitors in the MDD market include various selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and newer agents like esketamine nasal spray.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the CNS therapeutic area, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. There is a growing demand for novel treatments for neurological and psychiatric disorders due to increasing prevalence and the limitations of existing therapies.
Positioning
Relmada Therapeutics is positioned as a clinical-stage company with a focus on innovative, potentially first-in-class or best-in-class therapies for CNS disorders. Their competitive advantage lies in their novel drug candidates targeting specific mechanisms of action believed to address unmet needs.
Total Addressable Market (TAM)
The TAM for treatments of CNS disorders, including depression and epilepsy, is substantial and growing. For Major Depressive Disorder alone, the global market is valued in the tens of billions of dollars. Relmada Therapeutics is targeting a significant portion of this market with its lead candidate, aiming to capture market share with a differentiated treatment option.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with differentiated mechanisms of action.
- Focus on significant unmet medical needs in CNS disorders.
- Experienced management and scientific team.
Weaknesses
- Clinical-stage company with no approved products, leading to reliance on future approvals and funding.
- High costs associated with drug development and clinical trials.
- Potential for clinical trial failures.
Opportunities
- Addressing significant unmet needs in depression and other CNS disorders.
- Potential for partnerships or acquisitions by larger pharmaceutical companies.
- Growing market demand for innovative CNS treatments.
Threats
- Regulatory risks and potential delays in FDA approval.
- Competition from established and emerging therapies.
- Challenges in securing sufficient funding for ongoing development.
- Adverse clinical trial outcomes.
Competitors and Market Share
Key Competitors
- Johnson & Johnson (JNJ)
- Pfizer Inc. (PFE)
- AbbVie Inc. (ABBV)
- Bristol Myers Squibb Company (BMY)
Competitive Landscape
Relmada Therapeutics faces a competitive landscape with large, established pharmaceutical companies that have extensive resources for R&D, marketing, and distribution. Relmada's advantage lies in its specialized focus and potentially innovative approach to specific CNS disorders, aiming to capture niche markets or provide superior treatment options.
Growth Trajectory and Initiatives
Historical Growth: Relmada Therapeutics' historical growth is marked by the progression of its drug candidates through preclinical and clinical development stages. This involves increasing investment in R&D and expanding the scope of its clinical operations.
Future Projections: Future growth projections are contingent upon the successful completion of clinical trials, regulatory approvals, and subsequent commercialization of its drug candidates. Analyst estimates would reflect the perceived probability of success and market potential of its pipeline.
Recent Initiatives: Recent initiatives likely include advancements in ongoing clinical trials for REL-1017, potentially expanding into new indications, and strategic collaborations or partnerships to support development and commercialization.
Summary
Relmada Therapeutics is a clinical-stage biopharmaceutical company with a promising lead candidate, REL-1017, for depression. Its strengths lie in its focused approach and novel mechanism of action. However, it faces significant risks associated with clinical development, regulatory approval, and funding. The company needs to successfully navigate its clinical trials and secure future funding to capitalize on the substantial market opportunity in CNS disorders while managing intense competition.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations (Relmada Therapeutics Inc.)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Market Data Providers (e.g., Yahoo Finance, Google Finance)
- Pharmaceutical Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data and market share information are estimates and subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Relmada Therapeutics Inc
Exchange NASDAQ | Headquaters Coral Gables, FL, United States | ||
IPO Launch date 2014-10-09 | CEO & Director Dr. Sergio Traversa M.B.A., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.relmada.com |
Full time employees 17 | Website https://www.relmada.com | ||
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.